PLENDIL 5 MG
FELODIPINE : 5 MG · DIN 00851779 · GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE
Health Canada status: MARKETED
What is PLENDIL?
PLENDIL 5 MG contains FELODIPINE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 00851779, held by GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 07-Aug-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PLENDIL used for?
Treatment of mild to moderate essential hypertension.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00851779 |
|---|---|
| Brand name | PLENDIL |
| Generic / active ingredient | FELODIPINE : 5 MG |
| Manufacturer | GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE |
| Strength | 5 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C08CA02 FELODIPINE |
| AHFS class | 24:28.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-Aug-2024 |
| Original market date | 1992-12-31 00:00:00 |
How is it administered?
Initial: 5 mg once daily (2.5 mg for elderly/hepatic impairment). Maintenance: 2.5 to 10 mg once daily. Swallow whole; do not crush or chew. Avoid high-fat/carb meals and grapefruit juice.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 header present but content truncated), though typically 15-30°C for such forms.
How is it supplied?
Blister packages containing 30 tablets.
Contraindications
Hypersensitivity to felodipine or other dihydropyridines; women of childbearing potential, pregnancy, and lactation.
Warnings and precautions
May precipitate hypotension, reflex tachycardia, or myocardial ischemia. Use caution in heart failure or outflow obstruction. Can cause peripheral edema and gingival hyperplasia.
What can be used instead?
Other Canadian products sharing ATC code C08CA02 FELODIPINE. 8 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FELODIPINE | 10 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452383 |
| APO-FELODIPINE | 2.5 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452367 |
| APO-FELODIPINE | 5 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452375 |
| PLENDIL | 10 MG | TABLET (EXTENDED-RELEASE) | GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE | MARKETED | DIN 00851787 |
| PLENDIL | 2.5 MG | TABLET (EXTENDED-RELEASE) | GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE | MARKETED | DIN 02057778 |
| SANDOZ FELODIPINE | 10 MG | TABLET (EXTENDED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02280272 |
| SANDOZ FELODIPINE | 5 MG | TABLET (EXTENDED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02280264 |
| RENEDIL | 10 MG | TABLET (EXTENDED-RELEASE) | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02222000 |
| RENEDIL | 2.5 MG | TABLET (EXTENDED-RELEASE) | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02221985 |
| RENEDIL | 5 MG | TABLET (EXTENDED-RELEASE) | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02221993 |
Who else supplies FELODIPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FELODIPINE appears in 116 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.